Coherus BioSciences (CHRS) Competitors $1.12 +0.11 (+10.89%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.09 -0.03 (-2.68%) As of 04/17/2025 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CHRS vs. SIGA, DNA, SNDL, AUTL, RLAY, RAPP, ERAS, SANA, UPB, and PHATShould you be buying Coherus BioSciences stock or one of its competitors? The main competitors of Coherus BioSciences include SIGA Technologies (SIGA), Ginkgo Bioworks (DNA), SNDL (SNDL), Autolus Therapeutics (AUTL), Relay Therapeutics (RLAY), Rapport Therapeutics (RAPP), Erasca (ERAS), Sana Biotechnology (SANA), Upstream Bio (UPB), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry. Coherus BioSciences vs. SIGA Technologies Ginkgo Bioworks SNDL Autolus Therapeutics Relay Therapeutics Rapport Therapeutics Erasca Sana Biotechnology Upstream Bio Phathom Pharmaceuticals Coherus BioSciences (NASDAQ:CHRS) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment. Do institutionals & insiders believe in CHRS or SIGA? 72.8% of Coherus BioSciences shares are owned by institutional investors. Comparatively, 55.4% of SIGA Technologies shares are owned by institutional investors. 7.6% of Coherus BioSciences shares are owned by company insiders. Comparatively, 1.5% of SIGA Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate CHRS or SIGA? Coherus BioSciences presently has a consensus target price of $5.38, indicating a potential upside of 379.91%. Given Coherus BioSciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Coherus BioSciences is more favorable than SIGA Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus BioSciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75SIGA Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer CHRS or SIGA? Coherus BioSciences received 444 more outperform votes than SIGA Technologies when rated by MarketBeat users. Likewise, 65.26% of users gave Coherus BioSciences an outperform vote while only 23.81% of users gave SIGA Technologies an outperform vote. CompanyUnderperformOutperformCoherus BioSciencesOutperform Votes44965.26% Underperform Votes23934.74% SIGA TechnologiesOutperform Votes523.81% Underperform Votes1676.19% Which has better valuation & earnings, CHRS or SIGA? SIGA Technologies has lower revenue, but higher earnings than Coherus BioSciences. Coherus BioSciences is trading at a lower price-to-earnings ratio than SIGA Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoherus BioSciences$266.96M0.49-$237.89M$0.195.89SIGA Technologies$138.72M3.08$68.07M$0.827.30 Is CHRS or SIGA more profitable? SIGA Technologies has a net margin of 49.33% compared to Coherus BioSciences' net margin of -0.15%. SIGA Technologies' return on equity of 49.06% beat Coherus BioSciences' return on equity.Company Net Margins Return on Equity Return on Assets Coherus BioSciences-0.15% N/A -24.44% SIGA Technologies 49.33%49.06%38.72% Does the media favor CHRS or SIGA? In the previous week, Coherus BioSciences and Coherus BioSciences both had 5 articles in the media. SIGA Technologies' average media sentiment score of 1.10 beat Coherus BioSciences' score of 0.23 indicating that SIGA Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus BioSciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SIGA Technologies 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, CHRS or SIGA? Coherus BioSciences has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. SummarySIGA Technologies beats Coherus BioSciences on 9 of the 17 factors compared between the two stocks. Get Coherus BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRS vs. The Competition Export to ExcelMetricCoherus BioSciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$129.81M$2.84B$5.30B$7.34BDividend YieldN/A1.86%5.12%4.30%P/E Ratio-14.0030.4821.8417.80Price / Sales0.49441.91380.2597.71Price / CashN/A168.6838.2634.64Price / Book-0.643.466.443.98Net Income-$237.89M-$72.06M$3.22B$247.73M7 Day Performance33.99%2.54%2.85%1.80%1 Month Performance26.20%-15.71%-8.66%-6.97%1 Year Performance-44.00%-26.11%11.46%1.29% Coherus BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHRSCoherus BioSciences3.621 of 5 stars$1.12+10.9%$5.38+379.9%-47.9%$129.81M$266.96M-14.00330Analyst DowngradeNews CoverageSIGASIGA Technologies2.0565 of 5 stars$5.33-1.1%N/A-29.6%$380.76M$138.72M4.4440Options VolumeNews CoveragePositive NewsDNAGinkgo Bioworks0.6527 of 5 stars$6.39+14.8%$4.58-28.4%N/A$371.07M$227.04M-0.49640SNDLSNDL3.1316 of 5 stars$1.33-2.9%$3.63+172.6%-23.5%$349.49M$920.45M-4.29580AUTLAutolus Therapeutics2.1363 of 5 stars$1.31-1.5%$9.32+611.5%-70.5%$348.58M$10.12M-1.08330RLAYRelay Therapeutics2.7337 of 5 stars$2.05+2.5%$19.80+865.9%-56.7%$347.52M$10.01M-0.79330Analyst ForecastNews CoverageHigh Trading VolumeRAPPRapport Therapeutics1.7043 of 5 stars$9.51+5.8%$35.00+268.0%N/A$347.08MN/A-0.69N/AShort Interest ↑High Trading VolumeERASErasca3.3285 of 5 stars$1.23+5.6%$4.83+294.6%-37.0%$347.00MN/A-1.48120Short Interest ↓Gap DownSANASana Biotechnology2.3091 of 5 stars$1.53+3.4%$10.80+605.9%-80.0%$344.29MN/A-1.09380High Trading VolumeUPBUpstream BioN/A$6.36+4.3%$56.50+788.4%N/A$341.16M$2.37M0.0038Positive NewsPHATPhathom Pharmaceuticals3.7283 of 5 stars$4.87-0.2%$22.17+355.2%-58.9%$339.13M$55.25M-0.86110Analyst ForecastNews Coverage Related Companies and Tools Related Companies SIGA Technologies Alternatives Ginkgo Bioworks Alternatives SNDL Alternatives Autolus Therapeutics Alternatives Relay Therapeutics Alternatives Rapport Therapeutics Alternatives Erasca Alternatives Sana Biotechnology Alternatives Upstream Bio Alternatives Phathom Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CHRS) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CHRS Stock Free CHRS Stock Alerts